ClinicalTrials.gg
CompletedNCT03907540KD025-108Updated May 26, 2022Results posted

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

A Phase 1 interventional study of Belumosudil 200 mg tablet and [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose in Autoimmune Diseases and Fibrosis, sponsored by Kadmon Corporation, LLC. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-26.

Sponsored by Kadmon Corporation, LLC (part of Sanofi) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
30 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Autoimmune Diseases with a site in United Kingdom — 15 open to participants now, 22 under way, 11 of them phase 3. Autoimmune Diseases · United Kingdom.

Enrollment
63rd of 65
5 · median 94
Started
2019
with 3 others
Phase 1
15 of 73
1 open now
Registered
33rd of 73
by date

Among the 73 studies in Autoimmune Diseases with a site in United Kingdom, this one is the 63rd largest by enrollment of the 65 interventional ones that give a count, is one of 4 that started in 2019, is one of 15 in phase 1, and was the 33rd registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

15 of the 73 studies in Autoimmune Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 30 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Autoimmune Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

Human, absorption, metabolism and excretion study of belumosudil (KD025)

Read the detailed description

This is an open-label, 2-part study designed to assess the absolute bioavailability of belumosudil (KD025) and to determine the mass balance recovery, metabolite profile, and identification of metabolite structures for [14C]-KD025 in healthy male subjects.

Primary Objectives

  • To determine the absolute oral bioavailability of KD025 (Part 1)
  • To determine the mass balance recovery after a single oral dose of [14C]-KD025 (Part 2)
  • To provide plasma, urine, and fecal samples for metabolite profiling and structural identification (Part 2)

Secondary Objectives

  • To obtain information regarding the oral PK of total radioactivity, KD025 and its metabolites KD025m1 and KD025m2, in plasma
  • To obtain information regarding the intravenous (IV) pharmacokinetics (PK) of [14C]-KD025 in plasma (Part 1)
  • To determine the routes and rates of elimination of [14C]-KD025 and associated total radioactivity (Part 2)
  • To evaluate the extent of distribution of total radioactivity into blood cells (Part 2)
  • To assess the qualitative and quantitative metabolic profile of [14C]-KD025 and carry out the structural elucidation of the main metabolites in plasma (accounting for ≥ 10% of circulating total radioactivity) and in urine and fecal samples accounting for ≥ 10% of administered dose (Part 2)
  • To provide additional safety and tolerability information for belumosudil

PART 1:

Part 1 is an open-label, non-randomized single oral dose followed by an IV microtracer assessment in 5 healthy male subjects. Subjects receive a single oral dose of belumosudil (KD025) 200 mg Tablet (Treatment A), in the fed state following a standard breakfast on the morning of Day 1. Subjects then receive an IV dose of 100 μg [14C]-KD025 (a 'microdose') containing not more than (NMT) 37 kBq (kilobecquerel; 1000 nanocurie [nCi]) [14C], as a 15 min IV infusion (Treatment B), beginning 1.75 hours (h) after the oral dose administration (Treatment A), i.e., 15 minutes [min] before the expected time of maximum concentration [Tmax] 2 h) for the oral dose.

Planned enrollment is to be 6 subjects to ensure 4 evaluable subjects. An evaluable subject for Part 1 will be defined as a subject who had sufficient data for evaluation of the primary oral bioavailability objective of the study.

All subjects are to undergo preliminary screening procedures to determine their eligibility for Part 1 and Part 2 at the screening visit (Day -28 to Day -2 of Part 1). Subjects are to be admitted to the clinical unit on the evening prior to investigational medicinal product (IMP) administration (Day -1 of Part 1) for confirmation of eligibility and baseline procedures. Subjects will be dosed on the morning following admission (Day 1 of Part 1). Following an overnight fast (approximately 10 h), subjects are to consume a standard breakfast and receive a single dose of Belumosudil 200 mg Tablet (Treatment A) 30 min after the start of breakfast. At 1 h 45 min (1.75 h) after Treatment A administration, subjects are to receive an IV infusion of [14C]-KD025 solution, 100 µg (Treatment B). Subjects are to remain resident in the clinic until up to 48 hours post-oral dose (up to Day 3). The minimum washout period between dose administrations in Part 1 and 2 is 7 days.

PART 2:

Part 2 is an open-label, non-randomized absorption, distribution, metabolism, and elimination (ADME) assessment in 5 healthy male subjects. Following a minimum washout period of 7 days, subjects who participated in Part 1 of the study are to be admitted to the clinical unit for participation in Part 2 of the study. Subjects are to receive a single oral administration of [14C]-KD025 200 mg Capsule containing NMT 9.8 MBq (266 µCi) [14C] (Treatment C) in the fed state following a standard breakfast on the morning of Day 1.

A subject in Part 2 will be considered evaluable if they had provided biological samples for up to 168 hours after drug administration or demonstrates >90% mass balance recovery, or \< 1% of the administered dose eliminated in excreta for 2 consecutive days, whichever was sooner.

Approximately 7 days after subjects are discharged from Part 1 of the study, subjects are to be admitted to the clinical unit on the evening of the day prior to IMP administration (Day -1 of Part 2) for confirmation of eligibility and baseline procedures.

Subjects are to be dosed on the morning following admission (Day 1 of Part 2). Following an overnight fast (approximately 10 h), subjects consume a standard breakfast and receive a single dose of [14C]-KD025 200 mg Capsule (Treatment C) 30 min after the start of breakfast. Subjects are to remain in the clinic until up to 168 hours after dosing (up to Day 8 of Part 2). The plan is for subjects to be released as a group when all subjects had achieved a mass balance cumulative recovery of > 90% or if \< 1% of the dose administered had been collected in urine and feces within 2 separate consecutive 24-hour periods. This may result in the subjects being discharged as a group prior to completion of the planned residency period. Once the discharge criteria or the planned residency period is achieved, the subjects are to undergo discharge assessments; collection of all samples (blood, urine and feces) is stopped.

If mass balance criteria has not been met by all subjects on Day 8, the residency period for the subjects not achieving the release criteria may be extended up to a maximum of 216 h post-dose (Day 10 of Part 2). During the additional residency period, only urine and/or feces are to be collected. If the criterion is still not met by Day 10, or if additional residency not considered appropriate or necessary, then home collections of urine and/or feces may be requested at the discretion of the Investigator for individual subjects. To ensure ongoing well-being of subjects, a follow-up phone call will take place 5 to 7 days post-discharge from the study or after the end of the last collection period.

03

Conditions studied

  • Autoimmune Diseases
  • Fibrosis

Keywords

  • absorption
  • metabolism
  • excretion
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males
  2. Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), (ECG) and laboratory investigations (hematology, clinical chemistry and urinalysis)
  3. Body weight ≥ 50 kg
  4. (BMI) of 18.0 to 35.0 kg/m\^2
  5. Must be willing and able to communicate and participate in the whole study
  6. Must have regular bowel movements (i.e., average stool production of ≥ 1 and ≤ 3 stools per day)
  7. Subjects must have participated in Part 1 in order to be eligible for Part 2
  8. Must provide written
  9. Must agree to adhere to the requirements of the study

In addition to the above criteria, subjects must agree to the following restrictions:

  • No alcohol during the 24 hours prior to screening and the 24-hour prior to each admission until discharge from each part of the study.
  • No food or drinks containing grapefruit, cranberry, caffeine or other xanthines from 24 hours prior to each admission until discharge from each part of the study.
  • No food containing poppy seeds for 48 hours prior to screening and for 48 hours prior to each admission until discharge from each part of the study.
  • No unaccustomed strenuous exercise from the 72-hour period before the screening visit and then from 72 hours prior to each admission until discharge from each part of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who previously participated in any other study drug trial in which receipt of an investigational study drug occurred within 90 days prior to dosing
  2. Subjects who have previously participated in a study where subjects were dosed with belumosudil
  3. Subjects who are study site employees or immediate family members of a study site or sponsor employee
  4. Subjects with pregnant partners
  5. History of any drug or alcohol abuse in the past 2 years
  6. Regular alcohol consumption in males > 21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)
  7. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission
  8. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  9. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionizing Radiation Regulations 2017.
  10. Subjects who have been enrolled in an ADME/IV microtracer study in the last 12 months
  11. Subjects who do not have suitable veins for multiple venepunctures/cannulation
  12. abnormal biochemistry, hematology or urinalysis. Subjects with blood count, and red blood cells lower than the reference range
  13. Confirmed positive drugs of abuse test result
  14. Positive surface antigen (HBsAg), virus antibody (HCV Ab), or (HIV) results
  15. Evidence of renal impairment at screening as indicated by an estimated of \< 80 mL/min using the Cockcroft-Gault equation
  16. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder, as judged by the Investigator
  17. Subject has a history or presence of any of the following:

    • Active GI disease requiring therapy
    • Hepatic disease and/or or aspartate aminotransaminase > (ULN)
    • Renal disease and/or serum creatinine > upper limit of normal (ULN)
    • Other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
  18. Subject has corrected using Fridericia's formula (QTcF) intervals > 450 msec at screening or admission
  19. Serious adverse reaction or serious to any drug or the formulation
  20. Presence or history of clinically significant allergy requiring treatment
  21. Donation or loss of greater than 400 mL of blood within the previous 3 months
  22. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies in the 14 days before study drug administration.
  23. Failure to satisfy the Investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Part 1, Treatment A--Belumosudil 200 mg Tablet

    Belumosudil 200 mg tablet

    Drug: Belumosudil 200 mg tablet

  • Experimental
    Part 1, Treatment B--[14C]-KD025 IV Microdose

    \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution containing NMT 37 kBq (1000 nCi) \[14C\] over 15 min IV

    Drug: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose

  • Experimental
    Part 2, Treatment C--[14C]-KD025 Capsule

    \[14C\]-KD025 200 mg capsule containing NMT 9.8 MBq (215 μCi)

    Drug: [14C]-KD025 200 mg capsule

Interventions

  • Belumosudil 200 mg tablet, development candidate

    Also known as: Rezurock (brand name), KD025, SLx-2119

  • Drug[14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose

    test investigational medicinal product

  • test investigational medicinal product

06

What researchers measure

Primary outcomes

  1. Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV

    Apparent terminal elimination half-life (t\[1/2\] for Part 1: (Treatment A) KD025 200 mg tablet, fed (Day 1). then 1.75 hours later (Treatment B) \[14C\]-KD025 solution for infusion 20 microgm/mL (100 microgm in 5 mL) containing \<= 37 kilobecquerel as 15 min IV infusion 100 microgm, fed

    Time frame: Plasma samples belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dosing. Plasma samples [14C]-KD025 relative to end infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1,1.5,2,3,4,5,6,8,10,12,22,34, and 46 h

Secondary outcomes

  1. Part 1 Pharmacokinetics: Tmax for Belumosudil Tablet and [14C]-KD025

    Part 1: Time of maximum plasma concentration (Tmax) for belumosudil 200 mg oral tablet and \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV

    Time frame: Plasma samples belumosudil relative oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing. Plasma samples [14C]-KD025 relative to end infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,and 46 h

  2. Part 1 Pharmacokinetics: Cmax of Belumosudil Tablets

    The maximum concentration (Cmax) of belumosudil 200 mg tablets

    Time frame: Plasma samples belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.

  3. Part 1 Pharmacokinetics: Cmax of [14C]-KD025 IV

    The maximum concentration (Cmax) of belumosudil \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV

    Time frame: Plasma samples for [14C]-KD025 relative to end of infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,46 hours post-dose

  4. Part 1 Pharmacokinetics: AUC(0-inf) of Belumosudil Tablets

    The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of belumosudil 200 mg tablets

    Time frame: Plasma samples for belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.

  5. Part 1 Pharmacokinetics: AUC(0-inf) of [14C]-KD025 IV

    The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV

    Time frame: Plasma samples for [14C]-KD025 relative to end of infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,and 46 hours post-dose

  6. Part 1: Absolute Bioavailability of Belumosudil 200 mg Tablet

    The absolute bioavailability following oral administration of belumosudil 200 mg tablet, based on the area under the concentration-time curve from zero dosing extrapolated to infinity (AUC\[0-inf\])

    Time frame: Plasma samples for belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.

  7. Part 2: Mass Balance Recovery Following 200 mg Oral Dose of [14C]-KD025 Capsule

    Cumulative amount of total radioactivity excreted and recovered in urine, feces and total excreta (urine and feces combined) following dosing with \[14C\]-KD025 200 mg oral capsule.

    Time frame: Cumulative sample collection time frame 0-6 hours, 0-12 hours, 0-24 hours, 0-48 hours, 0-72 hours, 0-96 hours, 0-120 hours, 0-144 hours, 0-168 hours, 0-192 hours, 0-216 hours post-dose

  8. Part 2 Pharmacokinetics: Tmax of 200 mg [14C]-KD025

    Time of maximum concentration (Tmax) following a single oral dose of 200 mg \[14C\]-KD025 capsule

    Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose

  9. Part 2 Pharmacokinetics: t(1/2) of 200 mg [14C]-KD025

    Apparent terminal elimination half-life (t\[1/2\]) following a single oral dose of 200 mg \[14C\]-KD025 capsule

    Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose

  10. Part 2 Pharmacokinetics: Cmax of 200 mg [14C]-KD025

    Maximum concentration following a single oral dose of 200 mg \[14C\]-KD025 capsule

    Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose

  11. Part 2 Pharmacokinetics: AUC(0-inf) of 200 mg [14C]-KD025

    Area under the concentration-time curve from zero dosing extrapolated to infinity following a single oral dose of 200 mg \[14C\]-KD025 capsule

    Time frame: Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose

07

Results

Posted Sep 13, 2021

Participant flow

Participant flow — Overall Study
MilestoneAll Subjects (Part 1 and Part 2)
Started5
Completed part 15
Completed part 25
Completed5
Not completed0

Outcome measures

PrimaryPart 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV

Apparent terminal elimination half-life (t\[1/2\] for Part 1: (Treatment A) KD025 200 mg tablet, fed (Day 1). then 1.75 hours later (Treatment B) \[14C\]-KD025 solution for infusion 20 microgm/mL (100 microgm in 5 mL) containing \<= 37 kilobecquerel as 15 min IV infusion 100 microgm, fed

Time frame:
Plasma samples belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36, and 48 hours post-dosing. Plasma samples [14C]-KD025 relative to end infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1,1.5,2,3,4,5,6,8,10,12,22,34, and 46 h
Reported as:
Geometric mean · Hours
Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV
HoursPart 1: Treatment APart 1: Treatment B
Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV5.298 ± 66.75.857 ± 35.8
SecondaryPart 1 Pharmacokinetics: Tmax for Belumosudil Tablet and [14C]-KD025

Part 1: Time of maximum plasma concentration (Tmax) for belumosudil 200 mg oral tablet and \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV

Time frame:
Plasma samples belumosudil relative oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing. Plasma samples [14C]-KD025 relative to end infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,and 46 h
Reported as:
Median · Hours
Part 1 Pharmacokinetics: Tmax for Belumosudil Tablet and [14C]-KD025
HoursPart 1: Treatment APart 1: Treatment B
Part 1 Pharmacokinetics: Tmax for Belumosudil Tablet and [14C]-KD0252.000 (1.00 to 4.00)0.248 (0.24 to 0.25)
SecondaryPart 1 Pharmacokinetics: Cmax of Belumosudil Tablets

The maximum concentration (Cmax) of belumosudil 200 mg tablets

Time frame:
Plasma samples belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.
Reported as:
Geometric mean · ng/mL
Part 1 Pharmacokinetics: Cmax of Belumosudil Tablets
ng/mLPart 1 Treatment A
Part 1 Pharmacokinetics: Cmax of Belumosudil Tablets1870 ± 36.7
SecondaryPart 1 Pharmacokinetics: Cmax of [14C]-KD025 IV

The maximum concentration (Cmax) of belumosudil \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV

Time frame:
Plasma samples for [14C]-KD025 relative to end of infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,46 hours post-dose
Reported as:
Geometric mean · (pg/mL)/(ng equiv/mL)
Part 1 Pharmacokinetics: Cmax of [14C]-KD025 IV
(pg/mL)/(ng equiv/mL)Part 1: Treatment B
Part 1 Pharmacokinetics: Cmax of [14C]-KD025 IV4480 ± 18.0
SecondaryPart 1 Pharmacokinetics: AUC(0-inf) of Belumosudil Tablets

The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of belumosudil 200 mg tablets

Time frame:
Plasma samples for belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.
Reported as:
Geometric mean · (ng*h)/mL
Part 1 Pharmacokinetics: AUC(0-inf) of Belumosudil Tablets
(ng*h)/mLPart 1 Treatment A
Part 1 Pharmacokinetics: AUC(0-inf) of Belumosudil Tablets8300 ± 40.2
SecondaryPart 1 Pharmacokinetics: AUC(0-inf) of [14C]-KD025 IV

The area under the concentration-time curve from zero extrapolated to infinity (AUC\[0-inf\]) of \[14C\]-KD025 at a dose of 100 μg in a 5 mL solution IV

Time frame:
Plasma samples for [14C]-KD025 relative to end of infusion:-0.25,-0.16,-0.08,0,0.08,0.16,0.25,0.5,0.75,1, 1.5,2,3,4,5,6,8,10,12,22,34,and 46 hours post-dose
Reported as:
Geometric mean · ((ng*h)/mL)/(ng equiv*h/mL)
Part 1 Pharmacokinetics: AUC(0-inf) of [14C]-KD025 IV
((ng*h)/mL)/(ng equiv*h/mL)Part 1: Treatment B
Part 1 Pharmacokinetics: AUC(0-inf) of [14C]-KD025 IV6480 ± 29.3
SecondaryPart 1: Absolute Bioavailability of Belumosudil 200 mg Tablet

The absolute bioavailability following oral administration of belumosudil 200 mg tablet, based on the area under the concentration-time curve from zero dosing extrapolated to infinity (AUC\[0-inf\])

Time frame:
Plasma samples for belumosudil relative to oral dosing: 0,0.5,1,1.5,2,3,4,5,6,7,8,10,12,24,36, and 48 hours post-dosing.
Reported as:
Number · Percentage
Part 1: Absolute Bioavailability of Belumosudil 200 mg Tablet
PercentagePart 1: Treatment A
Part 1: Absolute Bioavailability of Belumosudil 200 mg Tablet64
SecondaryPart 2: Mass Balance Recovery Following 200 mg Oral Dose of [14C]-KD025 Capsule

Cumulative amount of total radioactivity excreted and recovered in urine, feces and total excreta (urine and feces combined) following dosing with \[14C\]-KD025 200 mg oral capsule.

Time frame:
Cumulative sample collection time frame 0-6 hours, 0-12 hours, 0-24 hours, 0-48 hours, 0-72 hours, 0-96 hours, 0-120 hours, 0-144 hours, 0-168 hours, 0-192 hours, 0-216 hours post-dose
Reported as:
Number · Percentage
Part 2: Mass Balance Recovery Following 200 mg Oral Dose of [14C]-KD025 Capsule
PercentageCumulative Urine Ae(%)Cumulative Feces Ae (%)Cumulative Total Ae (%)
0-6 (hours)2.194NANA
0-12 (hours)3.343NANA
0-24 (hours)3.77327.43131.203
0-48 (hours)3.93375.49979.432
0-72 (hours)3.95881.59785.555
0-96 (hours)3.96683.04487.010
0-120 (hours)3.97284.07088.042
0-144 (hours)3.97684.34088.315
0-168 (hours)3.97784.43688.413
0-192 (hours)3.97984.49384.472
0-216 (hours)3.98084.55388.533
SecondaryPart 2 Pharmacokinetics: Tmax of 200 mg [14C]-KD025

Time of maximum concentration (Tmax) following a single oral dose of 200 mg \[14C\]-KD025 capsule

Time frame:
Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
Reported as:
Median · Hours
Part 2 Pharmacokinetics: Tmax of 200 mg [14C]-KD025
Hours[14C]-KD025 Oral 200 mg KD025
Part 2 Pharmacokinetics: Tmax of 200 mg [14C]-KD0252.000 (1.50 to 2.05)
SecondaryPart 2 Pharmacokinetics: t(1/2) of 200 mg [14C]-KD025

Apparent terminal elimination half-life (t\[1/2\]) following a single oral dose of 200 mg \[14C\]-KD025 capsule

Time frame:
Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
Reported as:
Geometric mean · Hours
Part 2 Pharmacokinetics: t(1/2) of 200 mg [14C]-KD025
Hours[14C]-KD025 Oral 200 mg KD025
Part 2 Pharmacokinetics: t(1/2) of 200 mg [14C]-KD0255.109 ± 37.9
SecondaryPart 2 Pharmacokinetics: Cmax of 200 mg [14C]-KD025

Maximum concentration following a single oral dose of 200 mg \[14C\]-KD025 capsule

Time frame:
Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
Reported as:
Geometric mean · ng/mL
Part 2 Pharmacokinetics: Cmax of 200 mg [14C]-KD025
ng/mL[14C]-KD025 Oral 200 mg KD025
Part 2 Pharmacokinetics: Cmax of 200 mg [14C]-KD0251680 ± 32.1
SecondaryPart 2 Pharmacokinetics: AUC(0-inf) of 200 mg [14C]-KD025

Area under the concentration-time curve from zero dosing extrapolated to infinity following a single oral dose of 200 mg \[14C\]-KD025 capsule

Time frame:
Time Relative to Belumosudil Dosing: 0,0.5,1,1.5,2,3,4,5,6,8,10,12,24,36,48,72,96,120,144, and 168 hours post-dose
Reported as:
Geometric mean · (ng*h)/mL
Part 2 Pharmacokinetics: AUC(0-inf) of 200 mg [14C]-KD025
(ng*h)/mL[14C]-KD025 Oral 200 mg KD025
Part 2 Pharmacokinetics: AUC(0-inf) of 200 mg [14C]-KD0258100 ± 37.0

Adverse events

Collected over Up to 20 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent other events
Most frequent other events
EventAll Subjects
RashSkin and subcutaneous tissue disorders1/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Subjects
Mean53.0 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female0
Male5
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Subjects
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White4
More than one race0
Unknown or Not Reported1
Body Mass Index (kg/m^2)
Body Mass Index (kg/m^2)(kg/m^2)All Subjects
Mean27.86 ± 3.06
08

Study locations

1 site
  • Quotient Sciences Ltd
    Ruddington, Nottingham NG11 6JS, United Kingdom
09

References and documents

Publications

  • Schueller O, Skucas E, Regev G, Shaw I, Singh N, Sanghvi M, Croft M, Lohmer L, Alabanza A, Patel J. Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [14 C]-Belumosudil in Healthy Men: A Phase 1, Open-Label, 2-Part Study. Clin Pharmacol Drug Dev. 2022 Jul;11(7):786-794. doi: 10.1002/cpdd.1085. Epub 2022 Mar 1. PubMed 35231159 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in May 2019, 1 month.

Results were first posted in Sep 2021, 2 years 3 months after primary completion.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 1 month is below that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2019
First posted
Apr 9, 2019
StartActual
Apr 5, 2019
Primary completionActual
May 20, 2019
CompletionActual
May 20, 2019
Results first posted
Sep 13, 2021
Last update
May 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03907540
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Apr 9, 2019
Start date
Apr 5, 2019
Primary completion
May 20, 2019
Completion
May 20, 2019
Results posted
Sep 13, 2021
Last update
May 26, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion